Anti-pre-fusion viral F protein (MPE8)

Anti-pre-fusion viral F protein [MPE8], Recombinant, IgG1 kappa, Human
SKU
ABAAb03555-10.0
Packaging Unit
100 μg
Manufacturer
Absolute Antibody

Availability: loading...
Price is loading...
CloneID: MPE8

Antigen Long Description: The original antibody was generated by isolating IgG1 memory B cells of a blood donor with high serum neutralizing antibody titres against HRSV and HMPV.

Buffer Composition: PBS with 0.02% Proclin 300.

Available Custom Conjugation Options: AP, HRP, Fluorescein, APC, PE, Biotin Type A, Biotin Type B, Streptavidin, FluoroProbes 647H, Atto488, APC/Cy7, PE/Cy7

Uniprot Accession No.: P03420; Q6WB98

Specificity Statement: The antibody binds to HRSV, HMPV, bovine RSV (BRSV) and pneumonia virus of mice (PVM). The antibody binds to a highly conserved epitope that is displayed on the surface of the pre-fusion, but not of the post-fusion, HRSV and HMPV F proteins. The epitope is centred around the b2/b7 antiparallel strands and relies on residues T50, D305, G307, I309 and D310, which are highly conserved amongst 551 virus strains, comprising 364 HRSV, 162 HMPV, 8 BRSV and 5 PVM strains.

Application Notes (Clone): The antibody neutralized HRSV and HMPV, as well as PVM and BRSV, with IC50 (half-maximum inhibitory concentration) values ranging from 2 to 110 ng/ml. The antibody was also tested for its capacity to prevent cell-to-cell viral spread, showing a 50% spreading inhibiting capacity (IS50). The antibody selectively bound to the pre-fusion F protein, as shown by SPR. The antibody detected HRSV and HMPV F proteins under non-reducing conditions in western blot analysis. Further, the antibody showed prophylactic and therapeutic efficacy in vivo. In the HRSV mouse model, the antibody could reduce HRSV lung titres and was effective at concentrations as low as 0.12 mg per kg of body weight. Similar results were obtained in the HMPV mouse mode. The antibody fully protected mice from PVM lethality at 0.12 mg per kg and from body weight loss at 0.6 mg per kg. Moreover, in a therapeutic setting the antibody completely protected from lethality when administered up to 3 days after infection both at 30 and 5 mg per kg and conferred significant protection when given on day 4 or 5 at 30 mg per kg (Corti et al., 2013; PMID: 23955151). The structure of the scFv fragment in complex with the F protein of RSV was solved (Wen et al., 2017; PMID: 28134915). In ELISA analysis, the antibody bound to pre-fusion and uncleaved postfusion F, albeit with lower affinity (Gilman et al., 2015; PMID: 26161532).
More Information
SKU ABAAb03555-10.0
Manufacturer Absolute Antibody
Manufacturer SKU Ab03555-10.0
Package Unit 100 μg
Quantity Unit STK
Reactivity Virus
Clonality Recombinant
Application Western Blotting, ELISA, Neutralization, Surface Plasmon Resonance (SPR), In Vivo Assay, Inhibition
Isotype IgG1 kappa
Host Human
Product information (PDF)
×
MSDS (PDF) Download